While the drug industry and GOP lawmakers say the Inflation Reduction Act’s Medicare drug price negotiation program disincentivizes industry from developing new medicines, a recent policy brief by the health care research and advisory services firm ATI Advisory found most drug companies' innovation decisions in the first half of 2023 were more likely attributed to ongoing macroeconomic or company-specific trends rather than a direct result of the IRA. The firm says the same findings hold true for planned R&D spending...